Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: insights from ERS-COVID-19 study

Vista sencilla de ítem
dc.creatorLi, Dongze
dc.creatorChen, You
dc.creatorLiu, Hong
dc.creatorJia, Yu
dc.creatorLi, Fanghui
dc.creatorWang, Wei
dc.creatorWu, Jiang
dc.creatorWan, Zhi
dc.creatorCao, Yu
dc.creatorZeng, Rui
dc.date.accessioned2020-07-16T14:47:47Z
dc.date.available2020-07-16T14:47:47Z
dc.date.created2020-05-05
dc.description.abstractenglishDear Editor, A series of novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) since the end of 2019 is ongoing and triggering a global public health crisis. The estimated case fatality rate is approximately 3.4% in China. However, some patients experience dyspnea within 1 week and develop rapidly to organ injury and even death within 2 weeks after dyspnea.1 In addition, early organ injury could lead to higher risks of mortality. Thus, early identification of patients at risk of organ injury and death is crucial, which saves the patients from classified and invasive treatment, improving clinical outcome and prognosis. The human immune system plays significant roles in the resistance of foreign pathogens and the progress of pneumonia. Recent studies have mentioned that T cells were decreased in COVID-19 patients, excessive activated immune response was caused by pathogenic Th1 cells, and inflammatory CD14+CD16+ monocytes may connect to pulmonary immunopathology, leading to deleterious clinical manifestations and even acute mortality after SARS-CoV-2 infections.2 SARS-CoV-2 might damage lymphocytes, especially T lymphocytes, and the immune system was impaired during the period of disease to cause tissue injury.2,3spa
dc.format.extent3 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.1038/s41392-020-0163-5spa
dc.identifier.issn2059-3635 (online)spa
dc.identifier.otherhttps://www.nature.com/articles/s41392-020-0163-5spa
dc.identifier.urihttps://hdl.handle.net/20.500.12010/10639
dc.publisherSignal Transduction and Targeted Therapyeng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectERS-COVID-19spa
dc.subjectdyspneaspa
dc.subjectorgan injuryspa
dc.subjectpneumoniaspa
dc.subjectinmunopatología pulmonaspa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.titleImmune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: insights from ERS-COVID-19 studyspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.type.localArtículospa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China insights from ERS-COVID-19 study.pdf
Tamaño:
589.49 KB
Formato:
Adobe Portable Document Format
Descripción:
Documento Reservado
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
2.87 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Documentos científicos relacionados a la COVID-19

Carrera 4 # 22-61 Teléfono: (+57) 601 242 7030 - 018000111022 Fax: (+57) 601 561 2107 Bogotá D.C., Colombia

Fundación Universitaria de Bogotá Jorge Tadeo Lozano | Vigilada Mineducación

Institución de educación superior privada, de utilidad común, sin ánimo de lucro y su carácter académico es el de Universidad

Reconocimiento personería jurídica: Resolución 2613 del 14 de agosto de 1959 Minjusticia.

Institución de Educación Superior sujeta a inspección y vigilancia por el Ministerio de Educación Nacional.

Software DSpace copyright © 2002-2026 LYRASIS